Bioventus Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $568.1M | $573.3M | $512.3M | $512.1M | $430.9M |
| Gross profit | $388.2M | $388.2M | $328.2M | $331.1M | $302.7M |
| Operating income | $54.0M | -$15.2M | -$81.7M | -$167.2M | $12.1M |
| Cost of revenue | $179.9M | $185.1M | $184.2M | $181.0M | $128.2M |
| Cash from operations | $74.7M | $38.8M | $15.3M | -$13.5M | $23.0M |
| Capital expenditure | $2.6M | $1.0M | $7.4M | $1.5M | $13.5M |
| Free cash flow | $72.1M | $37.8M | $8.0M | -$15.0M | $9.5M |
| Impairments | $0 | $36.4M | $78.6M | $135.0M | $7.0M |
| Total assets | $683.6M | $728.0M | $810.9M | $1.4B | $1.2B |
| Total liabilities | $455.1M | $542.4M | $589.8M | $960.4M | $618.2M |
Shares outstanding 83.5M · Free float 34.8%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.